Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, Shen L. · 2017
Read Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. by Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, Shen L. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5390430.txt.
Description
Peiming Zheng and seven co-authors report a 2017 study in the Journal of Experimental and Clinical Cancer Research on drug resistance in stomach cancer. Cisplatin is a main drug for advanced cases, yet tumors often stop responding. The team asked whether immune cells that gather in tumors, called macrophages, pass that resistance to cancer cells through tiny shed sacs.
Macrophages of one type did make cancer cells resist the drug, and their sacs carried the effect. The sacs held high levels of a small RNA called miR-21. Once inside cancer cells, it lowered a brake protein, blocked cell death, and switched on a growth path. The authors say cutting this sac traffic could be a new way to treat stomach cancer.
Catalog record
| CREATOR | Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, Shen L. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |